SELLAS Life Sciences Group (NASDAQ:SLS) Trading Up 10% – Still a Buy?

Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) rose 10% on Friday . The company traded as high as $14.90 and last traded at $14.74. Approximately 4,624,310 shares traded hands during trading, a decline of 44% from the average session volume of 8,185,436 shares. The stock had previously closed at $13.40.

Analyst Ratings Changes

SLS has been the topic of several research reports. Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Friday, July 17th. Alliance Global Partners reiterated a “buy” rating on shares of SELLAS Life Sciences Group in a research report on Wednesday, August 12th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $10.00.

SELLAS Life Sciences Group Stock Performance

The business’s 50 day moving average price is $11.85 and its 200-day moving average price is $7.73. The company has a market cap of $3.12 billion, a price-to-earnings ratio of -73.62 and a beta of 2.48.

SELLAS Life Sciences Group (NASDAQ:SLS) last issued its earnings results on Tuesday, August 11th. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01).

Institutional Investors Weigh In On SELLAS Life Sciences Group

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in shares of SELLAS Life Sciences Group by 2.8% in the 3rd quarter. Vanguard Group Inc. now owns 6,839,905 shares of the company’s stock valued at $11,012,000 after purchasing an additional 185,106 shares during the period. Geode Capital Management LLC lifted its position in shares of SELLAS Life Sciences Group by 35.9% during the 4th quarter. Geode Capital Management LLC now owns 3,077,337 shares of the company’s stock worth $11,604,000 after buying an additional 812,953 shares during the period. Marshall Wace LLP lifted its position in shares of SELLAS Life Sciences Group by 23,550.0% during the 2nd quarter. Marshall Wace LLP now owns 2,715,489 shares of the company’s stock worth $5,947,000 after buying an additional 2,704,007 shares during the period. State Street Corp boosted its stake in SELLAS Life Sciences Group by 60.8% in the 4th quarter. State Street Corp now owns 2,188,171 shares of the company’s stock valued at $8,249,000 after buying an additional 827,257 shares in the last quarter. Finally, Millennium Management LLC boosted its stake in SELLAS Life Sciences Group by 341.0% in the 4th quarter. Millennium Management LLC now owns 1,387,849 shares of the company’s stock valued at $5,232,000 after buying an additional 1,073,147 shares in the last quarter. 17.38% of the stock is owned by institutional investors and hedge funds.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.